• Ticker

    Advertisement Find a Broker - Visit the DailyFinance Broker Center
DJIA 12,454.83 -74.92 -0.60%
NASDAQ 2,837.53 -1.85 -0.07%
S&P 500 1,317.82 -2.86 -0.22%

$33.57 $0.29 (0.87%)

REAL-TIME: Last trade at

Endo Pharmaceuticals

NASDAQ:ENDP

Jump to this page for:

Related Resources

Endo Health Solutions Inc. to Present at the Goldman Sachs 33rd Annual Global Healthcare Conference

5/25/2012 by PR Newswire

Endo Pharmaceuticals adopts new identity

5/23/2012 by Chain Drug Review

Endo Pharmaceuticals holders approve name change to Endo Health Solutions

5/23/2012 by Theflyonthewall.com

Endo Health Solutions Inc. Announced as New Name for Endo Pharmaceuticals Holdings Inc.

5/23/2012 by PR Newswire

Endo Pharmaceuticals sees FY12 adjusted EPS $5.00-$5.20, consensus $5.07

5/23/2012 by Theflyonthewall.com

Global Testosterone Replacement Therapy (TRT) Industry

5/21/2012 by PR Newswire

Cardinal bows to US drug agency

5/15/2012 by FT.com

BioDelivery Sciences provides update on operations and upcoming milestones

5/10/2012 by Theflyonthewall.com

BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its First Quarter 2012 Financials

5/10/2012 by PR Newswire

Cantor Fitzgerald Downgrades Endo Pharmaceuticals (ENDP) to Hold; Sidelined Ahead of Lidoderm Decision; M&A Unlikely N-T

5/2/2012 by StreetInsider.com

Endo Pharmaceuticals downgraded to Hold from Buy at Cantor

5/2/2012 by Theflyonthewall.com

Endo Pharmaceuticals Holdings' CEO Discusses Q1 2012 Results - Earnings Call Transcript

5/1/2012 by Seeking Alpha

Endo Pharmaceuticals (ENDP) Posts In-Line Q1 Earnings

5/1/2012 by iStockAnalyst

Endo Pharmaceuticals Swings To 1Q Loss On Litigation Impacts

5/1/2012 by NASDAQ

Endo Pharmaceuticals Holdings (ENDP) Reports In-Line Q1 EPS; Reaffirms Outlook

5/1/2012 by StreetInsider.com

Endo Pharmaceuticals sees FY12 CapEx $100M

5/1/2012 by Theflyonthewall.com

Endo Pharmaceuticals sees FY12 Pharmaceutical segment sales $1.74B-$1.8B

5/1/2012 by Theflyonthewall.com

Endo Pharmaceuticals returns to steady supply of Opana ER, Voltaren gel

5/1/2012 by Theflyonthewall.com

Endo Pharmaceuticals reports Q1 EPS 87c, consensus 87c

5/1/2012 by Theflyonthewall.com

Endo Reports First Quarter Financial Results And Announces Return To Steady Supply Of OPANA® ER And Voltaren® Gel

5/1/2012 by PR Newswire

Endo Pharmaceuticals to Announce First Quarter 2012 Financial Results on May 1, 2012

4/17/2012 by PR Newswire

Equity Research on Endo Pharmaceuticals Holdings Inc. and Allergan Inc. - Drug Manufacturers Acquiring and Expanding

4/16/2012 by StockHouse

Equity Research on Endo Pharmaceuticals Holdings Inc. and Allergan Inc. - Drug Manufacturers Acquiring and Expanding

4/16/2012 by Marketwire

Endo Pharmaceuticals risk/reward is compelling, says Cowen

4/16/2012 by Theflyonthewall.com

Qualitest Pharma announces FDA approval for Levetiracetam Oral Solution

4/12/2012 by Theflyonthewall.com

Qualitest Pharmaceuticals Receives FDA Approval for Levetiracetam Oral Solution, 100 mg/mL

4/12/2012 by PR Newswire

Critical Alerts for Sina, CF Industries, AOL, News Corp., and Endo Pharmaceuticals by Seven Summits Research

4/10/2012 by PR Newswire

Piper Jaffray's biotech and specialty pharma analysts hold a conference call

4/5/2012 by Theflyonthewall.com

Pharma Spin-Off Should Unlock Value of Covidien's Well-Positioned Device Business

4/5/2012 by Morningstar

Endo Announces Departure of American Medical Systems President

3/29/2012 by PR Newswire

Endo Pharmaceuticals tops its 10-day MA, resistance is at $37.64, then $38

3/23/2012 by Theflyonthewall.com

Endo Pharmaceuticals acquires Johnson Matthey's oxymorphone patent

3/22/2012 by Theflyonthewall.com

Endo Acquires Johnson Matthey's Oxymorphone Patent

3/22/2012 by PR Newswire

BioDelivery Sciences Provides Business Review and Update in Conjunction with Filing of its Annual Report

3/19/2012 by PR Newswire

Endo Pharmaceuticals initiated with a Buy at Cantor

3/15/2012 by Theflyonthewall.com

Endo Pharma files amended citizen petition for FDA resolution

3/13/2012 by Theflyonthewall.com

Endo Files Amended Citizen Petition Seeking Public FDA Resolution of Several Safety and Efficacy Issues Prior to Approval of a Generic Formulation of LIDODERM®

3/13/2012 by PR Newswire

Mersana Therapeutics Enters Collaboration With Endo Pharmaceuticals To Develop Next-Generation Antibody-Drug Conjugates

3/9/2012 by Biocompare

Harris & Harris Group Notes That Mersana Therapeutics Entered Into a Collaboration With Endo Pharmaceuticals

3/7/2012 by GlobeNewswire

Endo Pharmaceuticals Announces Proposal to Change Name of Parent Company and Rebrands Enterprise: Revealing an Innovative Corporate Structure Dedicated to Redefining Healthcare Value Four operating companies will provide integrated solutions across variou

3/1/2012 by Pharmaceutical and Medical Packaging News
See More Articles...